American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

( MENAFN - Swissinfo) Swiss medicines regulator Swissmedic has taken legal action against media houses in Switzerland for ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping n ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

This figure is $400 million below the low end of the company’s prior guidance and includes $3.5 billion from its type 2 ...

Times-Review, a CNHI newspaper. It does not necessarily reflect the opinion of The Tribune- Democrat. Forty percent of Americans are said to be obese. This has been going on for some time. Cheap ...

TOKYO (AP) — Asian shares traded mixed Tuesday, echoing Wall Street trading, where gains for oil-and-gas producers helped ...

Stocks gained ground on Wall Street following an encouraging update on inflation. The S&P 500 rose 0.3% in afternoon trading ...